Evidence map›Paper›PMID 37934581›Full record

ArticleAging2023

Polyphyllin I attenuates the invasion and metastasis via downregulating GRP78 in drug-resistant hepatocellular carcinoma cells.

Haiyan Du, Haochen Wu, Qinyang Kang, Mianmian Liao, Meirong Qin, Ning Chen, Houshuang Huang, Danping Huang, Ping Wang, Guangdong Tong

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. The role ofHeliyon · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Haiyan DuDepartment of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, China.
Haochen WuDepartment of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, China.
Qinyang KangDepartment of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, China.
Mianmian LiaoDepartment of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, China.
Meirong QinShenzhen Institute for Drug Control, Shenzhen 518000, Guangdong, China.
Ning ChenShenzhen Institute for Drug Control, Shenzhen 518000, Guangdong, China.
Houshuang HuangShenzhen Institute for Drug Control, Shenzhen 518000, Guangdong, China.
Danping HuangDepartment of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, China.
Ping WangShenzhen Institute for Drug Control, Shenzhen 518000, Guangdong, China.
Guangdong TongDepartment of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, China.
Guangzhou University of Chinese Medicine · CNShenzhen Institute for Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance to chemotherapy agents presents a major obstacle to the effective treatment of hepatocellular carcinoma (HCC), a common type of liver cancer. Increasing evidence indicates a link between drug resistance and the recurrence of HCC. Polyphyllin I (PPI), a promising pharmaceutical candidate, has shown potential therapeutic advantages in the treatment of sorafenib-resistant hepatocellular carcinoma (SR-HCC cells). In this study, we sought to investigate the mechanism underlying the inhibitory effect of PPI on the invasion and metastasis of SR-HCC cells. Our

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsCadherinsCell Line, TumorCell MovementCell ProliferationDiosgeninEndoplasmic Reticulum Chaperone BiPHumansMiceMice, NudeMolecular Docking SimulationPharmaceutical PreparationsSorafenibVimentinCadherinsDiosgeninEndoplasmic Reticulum Chaperone BiPPharmaceutical Preparationspolyphyllin ISorafenibVimentinGRP78hepatocellular carcinomainvasion and metastasisPolyphyllin Isorafenib-resistant

Identifiers

PMID37934581
PMCPMC10683619
OpenAlexW4388409544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.